R&D News | pharmaphorum

News

Deal-hungry Ipsen is at it again, pledging around $1bn for rights to an antibody-drug conjugate (ADC) for cancer developed by China's Simcere.

News

AstraZeneca has had a setback in its oncology pipeline, as AKT inhibitor ceralasertib fails to improve survival in a phase 3 lung cancer trial.

News

The BIOSECURE Act, now part of the NDAA, will put in motion US government-wide restrictions on ‘biotechnology companies of concern'.

News

Thanks to CEPI, Moderna's H5 bird flu vaccine can start a pivotal trial shelved after funding for the jab was pulled in the US by HHS Sec Kennedy.

News

Our latest crop of biofinancings has nine-figure rounds for Ambros, Atavistik, Orum, and Addition, with Link Cell and Aeovian also raising new funds.

News

Lilly breaks new ground for oral GLP-1 agonists with data showing it can help patients keep weight off after treatment with injectable therapies.